(Q28184438)

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

1 April 2024

author name string

Donna Bilu

1

0 references

D.N. Sauder

1

0 references

D. N. Sauder

2

1 reference

Europe PubMed Central

PubMed publication ID

14616337

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616337

full work available at URL

1 April 2024

language of work or name

English

0 references

publication date

November 2003

0 references

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.0366-077X.2003.05628.x

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.0366-077X.2003.05628.x/fullpdf

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

British Journal of Dermatology

1 April 2024

published in

0 references

volume

149 Suppl 66

0 references

149

0 references

issue

s66

0 references

page(s)

5-8

0 references

cites work

Immunomodulatory and pharmacologic properties of imiquimod

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Imiquimod: a cytokine inducer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Topical immunomodulators--progress towards treating inflammation, infection, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Immunomodulation as a treatment strategy for genital herpes: review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Imiquimod and resiquimod as novel immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

A review of the applications of imiquimod: a novel immune response modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Toll-like receptors: a family of pattern-recognition receptors in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Toll-like receptors: how they work and what they do.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Toll-like receptors: mammalian "taste receptors" for a smorgasbord of microbial invaders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Toll-like receptors and innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Toll-like receptors: critical proteins linking innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05628.X

Topical imiquimod: a review of its use in genital warts

21 January 2018

7

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6.

1 April 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells

1 April 2024

12

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

1 April 2024

26

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05628.X

1 April 2024

Identifiers